Somatostatin analog challenge test in the pre-surgical management of acth-secreting pheochromocytoma

4Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

ACTH-secreting pheochromocytoma is a very rare cause of Cushing’s syndrome, with a high morbidity and mortality risk due to both cortisol and catecholamines excess. We report the case of a 45-year-old female patient with a 3 cm, high-density, left adrenal mass, diagnosed as an ACTH-secreting pheochromocytoma. The biochemical sensitivity of the tumor to somatostatin analogues was tested by a 100 μg s.c. octreotide administration, which led to an ACTH and cortisol reduction of 50 and 25% respectively. In addition to alpha and beta blockers, preoperative approach to laparoscopic adrenalectomy included octreotide, a somatostatin analogue, together with ketoconazole, in order to achieve an adequate pre-surgical control of cortisol release. Histopathological assessment confirmed an ACTH-secreting pheochromocytoma expressing type 2 and 5 somatostatin receptors (SSTR-2 and-5).

Cite

CITATION STYLE

APA

Rossini, A., Perticone, F., Frosio, L., Lena, M. S., & Lanzi, R. (2019). Somatostatin analog challenge test in the pre-surgical management of acth-secreting pheochromocytoma. Endocrinology, Diabetes and Metabolism Case Reports, 2019(1). https://doi.org/10.1530/EDM-19-0123

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free